全球艾倫·赫恩登-達德利症候群治療市場（按治療類型、最終用戶和地區分類）

Global Allan-Herndon-Dudley Syndrome Treatment Market, By Treatment Type (Gene Therapy, Hormone Therapy), By End User (Hospital, Specialty Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球艾倫·赫恩登-達德利症候群治療市場規模估計為 1,410 萬美元，預計到 2032 年將達到 2,080 萬美元，2025 年至 2032 年的年複合成長率(CAGR)為 5.7%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	1410萬美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	5.70%	2032年價值預測	2080萬美元

數字。 2025 年艾倫·赫恩登-達德利症候群治療的全球市場佔有率（按地區）

艾倫·赫恩登-達德利症候群 (AHDS) 是一種由 MCT8 基因突變引起的罕見遺傳性疾病。這些突變導致甲狀腺激素跨血腦障壁的運輸受損。目前，AHDS 的治療選擇有限，且旨在控制症狀。首選治療方法是使用三碘甲狀腺原氨酸 (T3) 進行甲狀腺荷爾蒙補充療法。 T3 補充劑有助於恢復大腦中的甲狀腺激素水平，改善神經發育和功能。然而，高劑量的 T3 有時會引起震顫、過動和心律不整等副作用。另一種選擇是甲狀腺素 (T4) 療法，該療法依賴細胞內 T4 轉化為周邊活性形式 T3。這種間接治療方法效果不佳，因為 MCT8 突變會抑制荷爾蒙的運輸和活化。

新興基因療法是一種有前景的研究方法，可以直接治療 AHDS 的潛在遺傳原因。在基因治療中，將 MCT8 基因的健康副本引入患者的細胞或組織中，以取代突變的基因。儘管仍處於研究的早期階段，但這可以糾正激素運輸缺陷，並可能消除終生甲狀腺替代的需要。挑戰包括開發有效、安全的基因轉移載體，以及根據患者特定的 MCT8 突變為其量身定做治療方案。目前正在進行進一步的研究，以檢驗基因療法作為 AHDS 的潛在創新治療方法。

市場動態：

全球 Allan-Herndon-Dudley 症候群 (AHDS) (MCT8 缺乏症) 治療市場主要受到 AHDS 盛行率上升的推動，預計這將在預測期內推動市場成長。例如，美國生物技術資訊中心（NCBI）於2020年1月16日發布的數據顯示，在約15年的時間內已發現160多名受影響的個體，這表明該綜合症可能比以前認為的更為常見。

研究的主要特點

本報告對全球艾倫·赫恩登-達德利症候群 (AHDS) (MCT8 缺乏症) 治療市場進行了詳細分析，並給出了預測期 (2025-2032) 的市場規模和年複合成長率(CAGR)，假設 2024 年為基準年。
它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球艾倫·赫恩登-達德利症候群 (AHDS) (MCT8 缺乏症) 治療市場的主要企業是根據公司亮點、產品系列、關鍵亮點、業績和戰略等參數列出的。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球艾倫·赫恩登-達德利症候群 (AHDS) (MCT8 缺乏症) 治療市場報告針對該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過用於分析全球 Allan-Heldon-Dudley 症候群 (AHDS) (MCT8 缺乏症) 治療市場的各種策略矩陣來簡化決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 14.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.70%	2032 Value Projection:	USD 20.8 Mn

Allan-Herndon-Dudley syndrome (AHDS) is a rare genetic disorder caused by mutations in the MCT8 gene. These mutations result in impaired thyroid hormone transport across the blood-brain barrier. Current treatment options for AHDS are limited and aim to manage symptoms. The first line of treatment involves thyroid hormone replacement therapy with triiodothyronine (T3). T3 supplements help restore thyroid hormone levels in the brain to improve neurological development and function. However, high T3 doses sometimes cause side effects like tremors, hyperactivity, and irregular heartbeat. The other option is thyroxine (T4) therapy which relies on the peripheral conversion of T4 to active T3 within cells. This indirect method of treatment is not very effective as the MCT8 mutations disrupt hormone transportation and activation.

Emerging gene therapy is a promising investigational approach to directly treat the underlying genetic cause of AHDS. In gene therapy, a normal copy of the MCT8 gene would be delivered into the patient's cells and tissues to replace the mutated one. Though still in early research phase, this could correct the hormone transport defect and eliminate the need for lifelong thyroid supplementation. Challenges include developing effective and safe gene delivery vectors and treatments needing to be tailored to individual patients based on their specific MCT8 mutations. More research is underway to validate gene therapy as an innovative treatment for AHDS in the future.

Market Dynamics:

The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market is mainly driven by the increasing prevalence of AHDS is expected to propel the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in January 16, 2020, the identification of more than 160 affected individuals in approximately 15 years suggests that the syndrome is more common than previously thought.

Key features of the study:

This report provides an in-depth analysis of the global allan-herndon-dudley syndrome (AHDS) (MCT8 deficiency) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Rare Thyroid Therapeutics International AB and Erasmus Medical Center
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market

Detailed Segmentation:

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type
- Gene Therapy
- Hormone Therapy
Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User
- Hospital
- Specialty Clinics
- Others (Research institutes, etc.)
Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Company Profiles
- Rare Thyroid Therapeutics International AB
- Erasmus Medical Center

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of AHDS
- Increasing Healthcare Expenditure Globally
Key Highlights
Regulatory Scenario
Recent Trends
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others (Research institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2020-2032,(US$ Mn)
North Africa
Central Africa
South Africa